Navigation Links
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Date:4/9/2008

tainties. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including: statements regarding the Company's growth, future operating results, discovery, development of products and strategic alliances; statements regarding the potential number of patients eligible to benefit from VELCADE; statements regarding the merger agreement between Millennium and Takeda; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. Employees, investors and security holders are cautioned not to place undue reliance on these forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause Millennium's results to differ from expectations include: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; Millennium's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing Millennium's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; uncertainties as to the timing of the transactions contemplated by the merger agreement; uncertainties as to how many of the Millennium's stockholders will tender their stock in the Offer; the risk that competing offers will be made; the possibility that
'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Millennium Announces $200,000 Purchase Order From Greek Distributor
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Millennium Over-Delivers on 2007 Goals and Financial Guidance
4. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
5. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, Inc., ... has signed a long-term lease on Laboratory Drive in ... Carolina . The location will house review board ... provide high quality reviews and customer service to clients. ... represented Schulman in the deal, while Capital Associates ...
(Date:4/16/2015)... N.C. (PRWEB) April 16, 2015 ... Carolina at Charlotte (UNC Charlotte) spin-out company, announced ... L. Cooper, Ph.D., M.D., as Chief Operating Officer ... years of experience in developing clinical diagnostic and ... and infectious disease. , Cooper’s extensive career transcends ...
(Date:4/16/2015)... , April 16, 2015 /PRNewswire/ - Portage Biotech Inc. ... Securities Exchange: PBT.U), is pleased to announce that the ... on April 25, 2015 to be held in ... Gregory Bailey and Mr. James Mellon , ... an update on the key programs at its subsidiaries, ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a biopharmaceutical ... medicines in the areas of hepatitis C and,oncology, ... the first,quarter ended March 31, 2008., "We ... programs,during the first quarter," said Steve Worland, Ph.D., ...
... SAN CARLOS, Calif., April 30 Nektar,Therapeutics (Nasdaq: ... quarter ended March 31, 2008 on Wednesday, May 7, ... president and chief,executive officer, will host a conference call ... access the press release and a live audio-only Webcast ...
... Dohlsten, M.D., Ph.D., To Succeed As President, Wyeth Research ... WYE ),today announced that Robert R. Ruffolo, Jr., ... Vice President, Wyeth, later this,year. He will be succeeded ... Wyeth in November 2000 and has been responsible for,all ...
Cached Biology Technology:Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 8Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets 2Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement 2
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... starting March 30 th . The ... New York markets. Gino ... our new ad campaign following the recent initial shipment of ...
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... the virus, known as Seneca Valley Virus-001, reveals that it ... family, and confirms its recent designation as a separate genus ... shell looks like a craggy golf ballone with uneven divets ... in a round mesh rather like a whiffleball. "It ...
... delivery system that could lead to more efficient and ... by biomedical engineers at The University of Texas at ... molecules to significantly bolster a vaccine,s effectiveness while tailoring ... is most desirable for a particular disease, says Krishnendu ...
... This release is available in German . ... and CreutzfeldJakob disease in humans is a prion protein. This ... made of sugar and lipid components (a glycosylphosphatidylinositol, GPI) anchor. ... influence on the transformation of the normal form of the ...
Cached Biology News:Scripps research team solves structure of 'beneficial' virus 2RNA molecules, delivery system improve vaccine responses, effectiveness 2Tracking down the cause of mad cow disease 2
... LTQ XL extends the MSn performance of ... new tools to generate extensive structural information ... applications. , Multiple dissociation techniques (PQD, ... and unpredicted metabolites , Fast polarity switching ...
... Easy and Cost effective - Utilizes hands-off ... , No grinding - Extract DNA ... grinding tools between samples , Robust ... beat and homogenize without tube breakage , ...
... The LXQ linear ion trap mass ... paced analytical laboratory., The LXQ linear ion ... discovery and proteomic applications, delivering the fast ... Thermo linear ion trap at an attractive ...
... long and short-term enriched housing for nonhuman ... quarantine and non-quarantine settings on a per ... utilizing our state-of-the-art social housing and nursery ... on site CDC quarantine facilities. Primate ...
Biology Products: